25 completed, 6 not yet recruiting, 5 unknown, 4 recruiting. 44 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 44 | Completed 25, Not yet recruiting 6, Unknown 5, Recruiting 4, Withdrawn 3, Terminated 1 |
Follow Benign Prostatic Hyperplasia: new trials by email Literature Review of Benign Prostatic Hyperplasia trials Research Report on Benign Prostatic Hyperplasia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ceasing Alpha-blockers Early After Resection of the Prostate (The CLEAR Trial) Tamsulosin hydrochloride 0.2 mg, Placebo - Benign Prostatic Hyperplasia | Phase 4 | Not yet recruiting | Shanghai East Hospital | 400 | 2026-12-01 | 2026-09-29 |
| Perioperative Dutasteride for Hemorrhage Control in Bipolar TURP Under Anticoagulation. Dutasteride (0.5mg), Placebo - Benign Prostatic Hyperplasia, Postoperative Hemorrhage | Phase 4 | Not yet recruiting | Mohamed Mahmoud Dogha | 44 | 2026-10-21 | 2026-11-02 |
| Pupil Size and Choroidal Thickness Changes With Tamsulosin vs. Silodosin in Benign Prostatic Hyperplasia Patients tamsulosin 0.4mg, Silodosin 8 mg - Benign Prostatic Hyperplasia, Silodosin | Phase 4 | Not yet recruiting | Mohsen Pourazizi | 40 | 2026-08-01 | 2026-08-03 |
| Iris Structural Changes With Tamsulosin vs. Silodosin in Benign Prostatic Hyperplasia Patients tamsulosin 0.4mg, Silodosin 8 mg - Benign Prostatic Hyperplasia, Tamsulosin | Phase 4 | Not yet recruiting | Mohsen Pourazizi | 40 | 2026-08-01 | 2026-08-03 |
| Tamsulosin Dose Escalation or Silodosin Switch Before Trial Without Catheter in BPH-Related Acute Urinary Retention Tamsulosin 0.4 mg, Tamsulosin 0.8 mg, Silodosin 8 mg - Acute Urinary Retention, Benign Prostatic Hyperplasia | Phase 4 | Recruiting | Beni-Suef University | 378 | 2026-06-08 | 2026-06-16 |
| Tamsulosin With or Without Tadalafil for Trial Without Catheter After Acute Urinary Retention Due to Benign Prostatic Hyperplasia Tamsulosin, Tadalafil, Tadalafil Placebo - Acute Urinary Retention, Benign Prostatic Hyperplasia | Phase 4 | Recruiting | Beni-Suef University | 320 | 2026-06-08 | 2026-06-17 |
| The Combined Effect of Intravesical Botox Injections and HoLEP Surgery in Treating Benign Prostatic Hyperplasia and Overactive Bladder Intravesical Botox injection - Benign Prostatic Hyperplasia, Overactive Bladder | Phase 4 | Withdrawn | University Hospitals Cleveland Medical Center | 2026-06-01 | 2025-09-05 | |
| Tranexamic Acid for Bleeding Reduction During TURP Surgery Tranexamic Acid, Placebo (Normal Saline) - Benign Prostatic Hyperplasia, Transurethral Resection of the Prostate | Phase 4 | Recruiting | Hamza Najout | 80 | 2026-03-30 | 2026-10-09 |
| Silodosin vs Tamsulosin for LUTS Due to BPH: A Randomized Crossover Trial Silodosin, Tamsulosin - Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms | Phase 4 | Not yet recruiting | Ain Shams University | 140 | 2026-03-22 | 2026-03-16 |
| Effect of Tranexamic Acid on Intraoperative Blood Loss in Patients Undergoing Aquablation Tranexamic Acid (IV), Placebo - Benign Prostatic Hyperplasia | Phase 4 | Not yet recruiting | Kaiser Permanente | 56 | 2025-01-01 | 2024-11-29 |
| A Clinical Observation Study of a Chinese Patent Medicine Combined With Tamsulosin in Improving Sleep and Nocturia Symptoms After Enucleation of the Prostate Tamsulosin Hydrochloride Sustained-Release Capsules, Lingze Tablets - Benign Prostatic Hyperplasia, Nocturia Associated With Nocturnal Polyuria | Phase 4 | Recruiting | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | 136 | 2024-12-01 | 2026-01-22 |
| Role of Prophylactic Postoperative Antibiotics in HoLEP Nitrofurantoin, Cephalexin, Sulfamethoxazole Trimethoprim Combination - Benign Prostatic Hyperplasia, Urinary Tract Infections | Phase 4 | Withdrawn | Baylor Research Institute | 2023-03-01 | 2026-02-12 | |
| Self-Administered Nitrous Oxide (SANO) During Transrectal Prostate Biopsy to Reduce Patient Anxiety and Pain Self-Administered Nitrous Oxide, Oxygen - Prostate Disease, Malignancy | Phase 4 | Completed | Beth Israel Deaconess Medical Center | 143 | 2021-12-12 | 2024-01-30 |
| Efficacy And Safety Of Combination Therapy For Treatment Of Overactive Bladder In Male Patients With Benign Prostatic Hyperplasia. Mirabegron, Tamsulosin - Overactive Bladder, Benign Prostatic Hyperplasia | Phase 4 | Unknown | St. Joseph's Healthcare Hamilton | 200 | 2021-12-01 | 2021-03-19 |
| Efficacy of Tadalafil/Solifenacin VS Tamsulosin/Solifenacin Combination Therapy for BPH/OAB Tadalafil 5mg, Tamsulosin Hcl 0.4 mg, solifenacin 10 mg - Benign Prostatic Hyperplasia, Overactive Bladder | Phase 4 | Unknown | Mansoura University | 60 | 2021-11-08 | 2022-08-10 |
| Deprescribing Tamsulosin in Older Men Tamsulosin, Placebo - Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms | Phase 4 | Completed | University of California, San Francisco | 31 | 2021-09-18 | 2025-08-22 |
| Efficacy of Silodosin in the Treatment of Symptomatic Benign Prostatic Hyperplasia (BPH) Silodosin, Tamsulosin - Benign Prostatic Hyperplasia | Phase 4 | Completed | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 141 | 2017-08-31 | 2019-09-27 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH) Mirabegron, Placebo, Tamsulosin Hydrochloride - Benign Prostatic Hyperplasia, Overactive Bladder | Phase 4 | Completed | Astellas Pharma Global Development, Inc. | 715 | 2016-06-13 | 2024-11-12 |
| The Effects of α-adrenergic Receptor Antagonists on Choroid and Pupil Alfuzosin Hydrochloride 10 MG, Tamsulosin Hydrochloride 0.4 MG - Benign Prostatic Hyperplasia, Pupil Anomaly | Phase 4 | Completed | Kocatepe University | 63 | 2015-10-29 | 2017-05-09 |
| A Study of Tadalafil (LY450190) in Participants With Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia LUTS (BPH-LUTS). Tadalafil, Placebo, Alpha1 Blocker - Benign Prostatic Hyperplasia | Phase 4 | Completed | Eli Lilly and Company | 171 | 2015-04-01 | 2017-07-02 |
Showing 20 of 44. Sign in to see all of them.
Prostatic Hyperplasia (44) · Lower Urinary Tract Symptoms (7) · Urinary Bladder, Overactive (6) · Iris Diseases (2) · Nocturia (2) · Prostatic Neoplasms (2) · Anemia (1) · Anxiety Disorders (1) · Choroid Diseases (1) · Ejaculatory Dysfunction (1) · Erectile Dysfunction (1) · Hyperplasia (1) · Hypogonadism (1) · Hypotension, Orthostatic (1) · Neoplasms (1)
Genital Diseases (44) · Genital Diseases, Male (44) · Male Urogenital Diseases (44) · Urogenital Diseases (44) · Prostatic Diseases (43) · Pathological Conditions, Signs and Symptoms (18) · Signs and Symptoms (16) · Urological Manifestations (14) · Female Urogenital Diseases (7) · Female Urogenital Diseases and Pregnancy Complications (7) · Lower Urinary Tract Symptoms (7) · Urologic Diseases (7) · Urinary Bladder Diseases (6) · Eye Diseases (3) · Uveal Diseases (3)
Tamsulosin (17) · silodosin (8) · Dutasteride (7) · Tadalafil (4) · alfuzosin (4) · Doxazosin (2) · Saline Solution (2) · Solifenacin Succinate (2) · Tranexamic Acid (2) · mirabegron (2) · 5-alpha Reductase Inhibitors (1) · Adrenergic alpha-1 Receptor Antagonists (1) · Adrenergic alpha-Antagonists (1) · Anti-Inflammatory Agents, Non-Steroidal (1) · Celecoxib (1)
Samsung Medical Center (5) · Beni-Suef University (3) · Mansoura University (3) · Astellas Pharma Inc (2) · GlaxoSmithKline (2) · JW Pharmaceutical (2) · Mohsen Pourazizi (2) · Ain Shams University (1) · American Medical Systems (1) · Astellas Pharma Global Development, Inc. (1) · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (1) · Baylor Research Institute (1) · Beth Israel Deaconess Medical Center (1) · Eli Lilly and Company (1) · Hamza Najout (1)
United States (11) · Egypt (8) · South Korea (7) · Canada (3) · France (2) · Italy (2) · Japan (2) · United Kingdom (2) · Bangladesh (1) · China (1) · Czechia (1) · Germany (1) · Hungary (1) · Morocco (1) · Netherlands (1)
Kyu-Sung Lee, Ph.D (4) · Ahmed Elhefnawy (1) · Ahmed M Elshal, MD (1) · Alexis Te, MD (1) · Alvin M Matsumoto, MD (1) · Anil Kapoor, MD, FRCSC (1) · Benjmain N Breyer, MD, MAS (1) · Christopher F Tenggardjaja, MD (1) · Christopher R Chapple, MD (1) · Claus G Roehrborn, MD (1) · D.G. Moon, Prof (1)
PMID 21251673, PMID 21575967, PMID 37160401, PMID 42406401
2015 (1), K12DK111028 (1)